Elutia Inc. (ELUT) 주식 분석

회사 개요

Elutia Inc. is a commercial-stage medical device company dedicated to developing drug-eluting biomatrix products designed for surgical reconstruction and related clinical applications. The enterprise operates within the healthcare sector, specifically targeting the medical devices industry, where innovation in biomaterials and surgical tools drives market dynamics. As of the latest reporting period, the company maintains a market capitalization of $48.35 million while employing a workforce of 25 individuals. Its annual revenue over the trailing twelve months stands at $12.29 million. These financial figures indicate that Elutia functions as a small-cap entity with a relatively compact operational scale, yet it manages to generate significant revenue relative to its minimal employee base, suggesting a high degree of operational leverage or specialized focus within its niche of women's health and cardiovascular segments.

재무 건전성

The company reported a revenue of $12.29 million for the trailing twelve months, though it recorded a net loss of $15,871,000 and an EBITDA of $-17,196,000. The substantial gap between the positive revenue figure and the significant negative net income reveals a cost structure where operating expenses far exceed gross profits, which is characteristic of early-stage biotechnology and medical device firms investing heavily in research and development. Free cash flow stands at $-25,104,500, indicating that the company is currently burning cash rather than generating liquidity from its operations. This negative cash flow position implies limited immediate financial flexibility, necessitating reliance on existing cash reserves or external capital raises to fund ongoing development programs. The gross margin is reported at 53.7%, reflecting a healthy ability to control the cost of goods sold relative to sales, while the operating margin is a negative 167.9%, signaling that operating costs are disproportionately high compared to operating revenue. Furthermore, the profit margin figure of 434.2% appears anomalous in a loss-making scenario, likely resulting from accounting adjustments or non-operating income that offsets the operating losses on a specific reporting basis. On the balance sheet, the company holds $36.35 million in cash against $3.94 million in debt, resulting in a debt-to-equity ratio of 14.24. Despite the high leverage ratio, the absolute level of debt is low relative to cash holdings, suggesting a conservative approach to servicing obligations despite the equity dilution implied by the ratio. The current ratio is 2.22, which indicates a robust short-term liquidity position where current assets significantly exceed current liabilities, providing a buffer for operational continuity. Return on equity is listed as N/A due to the lack of attributable income, while return on assets is -23.4%, revealing that the asset base is currently generating negative returns on a total asset basis.

밸류에이션 평가

The trailing twelve-month P/E ratio is listed as N/A because the company is unprofitable, whereas the forward P/E is calculated at -1.03, reflecting the expectation of continued losses or negative earnings in the near term. The price-to-book ratio is 1.75, which indicates that the market values the company at a premium of 75% over its net book value, suggesting investor confidence in the intangible assets and future potential of its development pipeline. The price-to-sales ratio is 3.93, and the EV/EBITDA stands at -0.93; these alternative metrics suggest that valuation is driven primarily by revenue generation and asset base rather than current profitability, which is typical for pre-revenue or loss-making medical device companies. The stock has a 52-week high of $2.74 and a 52-week low of $0.50, establishing a trading range of $2.24. Without a specific current price provided in the facts, the valuation context relies on these extremes to show the potential volatility and the wide dispersion between the highest and lowest trading levels observed in the past year. The beta value is 0.71, which implies that the stock's price volatility is approximately 29% lower than that of the broader market, indicating a defensive or less volatile characteristic relative to the overall market index.

Growth & Income

Revenue growth year-over-year is recorded at 16.2%, demonstrating a strong expansion in top-line sales, while earnings growth is listed as N/A due to the company's negative net income. Since earnings are negative, a comparison of growth rates between earnings and revenue is not mathematically applicable in a traditional sense, but the positive revenue growth suggests that the company is successfully scaling its operations to fund its development programs. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This zero payout ratio indicates that the company retains all earnings—or rather, all available capital—to reinvest into its drug-eluting biomatrix programs rather than distributing returns to shareholders. Consequently, the overall growth and income profile of Elutia Inc. is characterized by capital reinvestment for expansion rather than income generation for investors, aligning with the lifecycle stage of a commercial-stage medical device firm focused on bringing NXT-41 and NXT-41x to market.